Taiwan-based clinical-stage drug developer Caliway Biopharmaceuticals (TWSE: 6919) said on Friday it has received authorisation from the Center for Drug Evaluation of China's National Medical Products Administration to proceed with CBL-0102, its China clinical trial for CBL-514, an injectable candidate for large-area localised fat reduction.
The clearance was granted earlier than anticipated, accelerating the programme's development timeline in China.
Subject enrolment is expected to begin in December 2026, with the study scheduled for completion in the second quarter of 2027 and clinical data anticipated shortly afterwards. Caliway Biopharmaceuticals said the results will support subsequent clinical development activities and regulatory submissions.
The randomised, open-label, single-dose study is expected to enrol around 30 healthy participants across two sites in China. It is designed to assess the effects of ethnic factors on the pharmacokinetic profile, safety and tolerability of CBL-514 in a Chinese population.
According to the company, data from Asian participants could support future Phase 3 studies and regulatory filings in China, while also informing submissions in other Asian markets.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial